A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2026

Conditions
Posttraumatic Stress Disorder
Interventions
BEHAVIORAL

Prolonged Exposure Therapy

A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

DRUG

Pharmacotherapy with paroxetine or venlafaxine XR

Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression

Trial Locations (7)

19104

RECRUITING

Corporal Michael J. Crescenz VA Medical Center, Philadelphia

19320

RECRUITING

Coatesville VA Medicial Center, Coatesville

35233

RECRUITING

Birmingham VA Healthcare System, Birmingham

53295

RECRUITING

Milwaukee VA Medical Center, Milwaukee

75216

ACTIVE_NOT_RECRUITING

VA North Texas Healthcare System, Dallas

92161

ACTIVE_NOT_RECRUITING

VA San Diego Healthcare System, San Diego

94025

ACTIVE_NOT_RECRUITING

VA Palo Alto Healthcare System, Menlo Park

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Corporal Michael J. Crescenz VA Medical Center

FED

collaborator

Coatesville VA Medical Center

UNKNOWN

collaborator

Milwaukee VA Medical Center

FED

collaborator

North Texas Veterans Healthcare System

FED

collaborator

San Diego Veterans Healthcare System

FED

collaborator

VA Palo Alto Health Care System

FED

collaborator

Birmingham VA Health Care System

FED

lead

University of Pennsylvania

OTHER